title: Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.
authors.forename: A
authors.initials: A
authors.lastname: Bermúdez
authors.forename: F
authors.initials: F
authors.lastname: Marco
authors.forename: E
authors.initials: E
authors.lastname: Conde
authors.forename: E
authors.initials: E
authors.lastname: Mazo
authors.forename: M
authors.initials: M
authors.lastname: Recio
authors.forename: A
authors.initials: A
authors.lastname: Zubizarreta
mesh_terms: D000361:Agammaglobulinemia / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D006562:Herpes Zoster / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007116:Immunization, Passive; D016867:Immunocompromised Host; D008224:Lymphoma, Follicular / Q000150:complications / Q000188:drug therapy* / Q000628:therapy; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D014781:Viscera / Q000473:pathology / Q000821:virology
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone